Meeting
2016 ASCO Annual Meeting
SELECT-4: Phase I dose escalation trial of selumetinib (AZD6244, ARRY-142886) in combination with durvalumab (MEDI4736) in patients with advanced solid tumors.
Authors
Pasi A. Janne
Dana-Farber Cancer Institute, Boston, MA
Pasi A. Janne , Dana C. Ghiorghiu , Paul D. Smith , Riccardo Belli , Phillip A. Dennis , Gabriella Lucia Mariani
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Small Molecules
Clinical Trial Registration Number
NCT02586987
Citation
J Clin Oncol 34, 2016 (suppl; abstr TPS2607)
DOI
10.1200/JCO.2016.34.15_suppl.TPS2607
Abstract #
TPS2607
Poster Bd #
299a
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
A phase 1 study to evaluate the safety and tolerability of MEDI4736, an anti–PD-L1 antibody, in combination with tremelimumab in patients with advanced solid tumors.
First Author: Margaret K. Callahan
Poster
2016 ASCO Annual Meeting
A phase 1 study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of MEDI9447 alone and in combination with durvalumab (MEDI4736) in patients with advanced solid tumors.
First Author: Johanna C. Bendell
Poster
2016 ASCO Annual Meeting
Safety and clinical activity of durvalumab (MEDI4736), an anti-PD-L1 antibody, in treatment-naïve patients with advanced non‒small-cell lung cancer.
First Author: Scott Joseph Antonia
Poster
2015 ASCO Annual Meeting
Phase I study to evaluate the safety and tolerability of MEDI4736, an anti-programmed cell death ligand-1 (PD-L1) antibody, in Japanese patients with advanced solid tumors.
First Author: Haruo Iguchi